Further Data from Phase 2 Statins Trial in Progressive MS Show Effect on Cognition: Phase 3 Study Underway
June 9, 2017
New data have been published from a completed phase 2 study of the cholesterol-lowering drug simvastatin in people with secondary progressive MS, indicating improvements in some aspects of cognitive function after 2 years among those given simvastatin. Previously reported results suggested that simvastatin reduced the rate of brain atrophy, or shrinkage. A large phase 3 trial of simvastatin is
underway, with co-funding from the National MS Society and others, being led by Dr. Jeremy Chataway (University College London).
Read the scientific paper, and the accompanying editorial
Read more about the phase 3 statins trial
Multiple sclerosis is an unpredictable disease of the central nervous system. Currently there is no cure. Symptoms vary from person to person and may include disabling fatigue, mobility challenges, cognitive changes, and vision issues. An estimated 1 million people live with MS in the United States. Early diagnosis and treatment are critical to minimize disability. Significant progress is being made to achieve a world free of MS.
The National MS Society, founded in 1946, is the global leader of a growing movement dedicated to creating a world free of MS. The Society funds cutting-edge research for a cure, drives change through advocacy and provides programs and services to help people affected by MS live their best lives. Connect to learn more and get involved: nationalMSsociety.org, Facebook, X, formerly known as Twitter, Instagram, YouTube or 1-800-344-4867.